White 2002.

Methods	1‐ to 2‐week wash‐out period for patients who were currently receiving antihypertensive therapy; 2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg during 2 consecutive weeks of run‐in; also required that ambulatory awake DBP >/= 85 mm Hg; 8‐week total double‐blind treatment, 4‐week low‐dose treatment (week 0‐4), forced titration at week 4 to high‐dose, 4‐week high‐dose treatment (week 4‐8)
Participants	Losartan 50 mg: n=103(64 males,39 females); mean age=55(10) years; baseline SBP=148(14) mm Hg, DBP=95(7) mm Hg, HR=72(9) bpm; Placebo: n=46(30 males,16 females); mean age=56(11) years; baseline SBP=148(12) mm Hg, DBP=95(6) mm Hg, HR=71(9) bpm
Interventions	Losartan 50 mg once daily; Placebo; administered in the morning
Outcomes	Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer; WDAE
Notes	Used week BP data only; BP change and SD of change reported; BP data from Table IV, p. 663; Jadad score=3; funding source= not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear

BP=blood pressure, DBP=diastolic blood pressure; SBP=systolic blood pressure; SD=standard deviation; WDAE=withdrawal due to adverse effects; ITT=intention‐to‐treat; bpm=beats per minute